¡Atención! Este sitio usa cookies y tecnologías similares.

Si no cambia la configuración de su navegador, usted acepta su uso. Saber más



Bibliografía carnitina


  • Amin KA, Nagy MA. Effect of Carnitine and herbal mixture extract on obesity induced by high fat diet in rats. Diabetol Metab Syndr. 2009;1(1):17.
  • Andreozzi GM. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease. Expert Opin Pharmacother. 2009;10(16):2697-707.
  • Arduini A, Bonomini M, Savica V, Amato A, Zammit V. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther. 2008;120(2):149-56.
  • Asilsoy S, Bekem O, Karaman O, Uzuner N, Kavukçu S. Serum total and free carnitine levels in children with asthma. World J Pediatr. 2009;5(1):60-2.
  • Bloomer RJ, Smith WA. Oxidative stress in response to aerobic and anaerobic power testing: Influence of exercise training and carnitine supplementation. Res Sports Med 2009;17:1-16.
  • Borghi-Silva A, Baldissera V, Sampaio LM, Pires-DiLorenzo VA, Jamami M, Demonte A, Marchini JS, Costa D. L-carnitine as an ergogenic aid for patients with chronic obstructive pulmonary disease submitted to whole-body and respiratory muscle training programs. Braz J Med Biol Res. 2006;39(4):465-74.
  • Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, Attisano T, Ambrosio G, Siliprandi N, Angelini C.Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77(4):767-73.
  • Brevetti G, Diehm C, Lambert D.European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34(5):1618-24.
  • Cha YS. Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. Asia Pac J Clin Nutr. 2008;17 Suppl 1:306-8.
  • Costell M, O’Connor J, Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans. Biochem Biophys Res Commun 1989;161:1135- 43.
  • Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, Fleishman S, Lapin J, Klein E, Lesage P, Portenoy R, Esteban-Cruciani N. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci. 2004;1033:168-76.
  • Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J, Portenoy RK, Esteban-Cruciani N. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. Pain Symptom Manage. 2009;37(4):622-31.
  • Davis PA, Mormino P, Savica V, Calò LA. L-carnitine, inflammation and hypertension. Nephrology 2009;14:264-265.
  • De Grandis D.Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs. 2007;21 Suppl 1:39-43; discussion 45-6.
  • Eder K, Felgner J, Becker K, Kluge H. Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds. Int J Vitam Nutr Res. 2005;75(1):3-9.
  • Erguven M, Yilmaz O, Koc S, Caki S, Ayhan Y, Donmez M, Dolunay G. A case of early diagnosed carnitine deficiency presenting with respiratory symptoms. Ann Nutr Metab. 2007;51(4):331-4.
  • Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C: Therapeutic effects of L-carnitine propionyl-L-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci 2004, 1033:79-91.
  • Hathcock JN, Shao A. Risk assessment for carnitine. Reg Tox Pharmacology 2006;46:23-28.
  • Hoppel C.The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis. 2003;41(4 Suppl 4):S4-12.
  • Irat AM, Aktan F, Ozansoy G. Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol 2003;55:1389-95.
  • Kendler BS.  Supplemental conditionally essential nutrients in cardiovascular disease therapy. J. Cardiovasc Nurs. 2006 Jan-Feb;21(1):9-16.
  • Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M: L-carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 2009, 89(1):71-76.
  • Marriage B, Clandinin MT, Glerum DM. Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc. 2003;103(8):1029-38.
  • Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, Stevens RD, Hegardt FG, Muoio DM. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem. 2009 Aug 21;284(34):22840-52.
  • aRajasekar P, Anuradha CV. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Acta Diabetol. 2007;44(2):83-90.
  • bRajasekar P, Anuradha CV: Effect of L-carnitine on skeletal muscle lipids oxidative stress in rats fed high-fructose diet. Exp Diabetes Res. 2007, 2007:72741.
  • Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000;139:S120 -3.
  • Sinatra ST. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern Ther Health Med 2009;15(3):44-52.
  • Soukoulis V, Dihu JB, Sole M, Anker SD, Cleland J, Fonarow GC, Metra M, Pasini E, Strzelczyk T, Taegtmeyer H, Gheorghiade M. Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol. 2009 27;54(18):1660-73.
  • Uzuner N, Kavukcu S, Yilmaz O, Ozkal S, Islekel H, Karaman O, et al. The role of L-carnitine in treatment of a murine model of asthma. Acta Med Okayama 2002;56:295-301.
  • Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology. 1995; 32 (3):132-8.
  • Porter NS, Jason LA, Boulton A, Bothne N, Coleman B.Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J Altern Complement Med. 2010 Mar;16(3):235-49.
  • Reuter SE, Evans AMLong-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. J Intern Med. 2011 Jul; 270 (1):76-84. doi: 10.1111/j. 1365-2796. 2010. 02341. Epub 2011 Jan 19).
  • Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev. 2000 Apr;5(2):93-108.